相关临床试验
19
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
4
21.1%
已完成
11
57.9%
招募中
4
21.1%
暂无批准数据
- NewAmsterdam Pharma reported encouraging MACE event rates in its PREVAIL cardiovascular outcomes trial, tracking in line with Phase 3 BROADWAY results, with EMA approval decision expected in second half 2026. - The company demonstrated statistically significant reductions in p-tau217, a key Alzheimer's disease biomarker, with obicetrapib showing 20.5% reduction in highest-risk ApoE4/E4 carriers over 12 months. - Three Phase 3 trials are ongoing including PREVAIL (9,500+ patients), REMBRANDT (coronary plaque imaging), and newly initiated RUBENS for metabolic syndrome patients. - The company plans to launch its first dedicated Alzheimer's disease trial in 2026 based on positive biomarker data from BROADWAY analysis.
- Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke. - The trial enrolled over 12,000 high-risk patients followed for 4.5 years, with approximately 85% maintained on high-intensity or moderate LDL-C reducing therapy. - Repatha becomes the first and only PCSK9 inhibitor proven to reduce cardiovascular events in high-risk adults without prior cardiovascular events, potentially expanding treatment to tens of millions more patients. - The data supports Amgen's recently approved FDA label expansion for Repatha in adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL cholesterol.
- The European Medicines Agency has validated Marketing Authorization Applications for obicetrapib monotherapy and obicetrapib-ezetimibe combination therapy, marking a significant regulatory milestone for NewAmsterdam Pharma. - Phase 3 trials demonstrated clinically meaningful LDL-C reductions of 35-40% with obicetrapib monotherapy and approximately 50% with the combination therapy, both showing safety profiles comparable to placebo. - The partnership with Menarini Group provides NewAmsterdam with potential milestone payments up to €863 million and tiered double-digit royalties, while Menarini handles European commercialization responsibilities. - With cardiovascular disease causing 17.9 million deaths annually and many patients failing to reach LDL-C targets despite existing therapies, obicetrapib could address a significant unmet medical need.
• NLS Pharmaceutics has filed a $75 million mixed securities shelf, signaling potential capital raising activities to support its clinical development pipeline in the near future. • NewAmsterdam Pharma has filed a significantly larger $500 million mixed securities shelf, positioning the company for substantial financing flexibility as it advances its cardiovascular therapeutics. • These strategic financial moves by both pharmaceutical companies indicate preparation for expanded research operations, clinical trials, or possible acquisitions in a competitive biotech funding landscape.
• NewAmsterdam Pharma reported positive Phase 3 results for obicetrapib, demonstrating significant LDL-C reduction and a favorable safety profile. • The company plans to present additional data from BROADWAY, BROOKLYN, and TANDEM trials throughout 2025 to support regulatory filings. • NewAmsterdam is focusing on commercial readiness, including scaling up manufacturing and building inventory for potential U.S. and European launches. • The company is also continuing Phase 2 and Phase 3 trials to evaluate obicetrapib's effects on lipoprotein(a) and coronary plaque, respectively.
- Rilzabrutinib demonstrated a 65% platelet response rate in ITP patients in the Phase 3 LUNA 3 trial, compared to 33% in the placebo group, supporting its potential as a first-in-class treatment. - Obicetrapib's Phase 3 BROADWAY trial showed a significant reduction in major adverse cardiovascular events, highlighting its multifaceted mechanism of action beyond LDL cholesterol lowering. - Both rilzabrutinib and obicetrapib have received 'Buy' ratings from analysts, driven by strong efficacy, safety profiles, and potential market positioning in their respective therapeutic areas.
• Merck's sotatercept (Winrevair) met the primary endpoint in the Phase 3 ZENITH trial, demonstrating potential in treating pulmonary arterial hypertension. • A fixed-dose combination of obicetrapib and ezetimibe nearly halved LDL cholesterol in statin-resistant patients, according to NewAmsterdam Pharma. • Real-world data indicates improved outcomes with the Sapien 3 Ultra Resilia TAVR valve compared to older models, Edwards Lifesciences reported.
• NewAmsterdam Pharma's Phase 3 TANDEM trial reveals that a fixed-dose combination of obicetrapib and ezetimibe significantly reduces LDL-C levels in cardiovascular disease patients. • The trial met its primary endpoint, demonstrating a 50% reduction in LDL-C compared to placebo, with over 70% of patients achieving LDL-C levels below 55 mg/dL. • The combination treatment was well-tolerated, aligning with previous safety data, and is expected to support global regulatory filings for NewAmsterdam Pharma.
• NewAmsterdam Pharma's fixed-dose combination of obicetrapib and ezetimibe met its primary endpoint in a Phase III trial, demonstrating robust LDL-C reduction. • The study's consistent data supports the potential of the combination therapy for managing cholesterol levels in patients. • Despite positive results, investor concerns regarding specific findings led to a decrease in the company's stock price. • The CEO of NewAmsterdam Pharma emphasized the importance of outcomes, highlighting the clinical significance of the trial data.
- NewAmsterdam Pharma's Obicetrapib significantly reduced LDL-C by 33% in patients with ASCVD and/or HeFH on maximally tolerated lipid-lowering therapies. - The BROADWAY trial observed a 21% reduction in major adverse cardiovascular events (MACE) with Obicetrapib at one year. - Obicetrapib demonstrated a favorable safety profile, comparable to placebo, with similar rates of treatment discontinuation and adverse events. - NewAmsterdam plans regulatory filings in 2025, presenting further data at upcoming scientific sessions.
